New study checks drug safety for prostate cancer patients
NCT ID NCT04621669
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how an experimental drug called SHR3680 affects the way the body processes three other common drugs: digoxin, rosuvastatin, and metformin. Thirty-six men with prostate cancer took SHR3680 along with these drugs to see if there were any interactions. The goal was to gather safety information, not to test if SHR3680 works against cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR3680 (an experimental drug for prostate cancer)
- What this could lead to
- If successful, this study will help doctors understand how to safely combine SHR3680 with other common medications.
- What could go wrong
- This is an early, small study focused on drug interactions, not on treating cancer itself. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG-DRUG INTERACTION,SHR3680 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks